1. Long-Term Hormonal Therapy: Who Would Benefit?
François Desgrandchamps 
European Urology Supplements 
Volume 9, Issue 8, Pages (October 2010)
DOI: /j.eursup
Copyright © 2010 European Association of Urology Terms and Conditions

2. Fig. 1
– Prostate cancer–related deaths with immediate versus delayed treatment in patients with advanced prostate cancer. Reproduced with permission from [4].
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

3. Fig. 2
– Baseline prostate-specific antigen (PSA) levels as a prognostic marker of mortality in (A) immediate and (B) deferred treatment. Reprinted from [6], Copyright (2008), with permission from Elsevier.
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

4. Fig. 3
– Immediate versus deferred androgen-deprivation therapy (ADT) in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. CI=confidence interval. Reprinted from [7], Copyright (2006), with permission from Elsevier.
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

5. Fig. 4
– Overall survival rates in patients with prostate cancer treated with either radiation therapy (RT) with hormonal therapy (HT) at relapse or with RT with adjuvant HT. Reprinted from [9], Copyright (2005), with permission from Elsevier.
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions